RNS Number : 4440K IQ-AI Limited 05 May 2022   5 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   Notice of AGM   IQ-AI Limited announces that notice of the annual general meeting of the Company, to be held at Third Floor, Forum 4, Grenville Street, St Helier, Jersey, JE2 4UF on 30

RNS Number : 1476K IQ-AI Limited 03 May 2022   3 May 2022   IQ-AI Ltd (“IQ-AI” or the “Company”)   IB Neuro’s Quantitative Mapping Method Assesses Metastatic Tumors Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue Milwaukee – 3 May 2022:  Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF)

– Article source

RNS Number : 7683J IQ-AI Limited 28 April 2022   28 April 2022 IQ-AI Ltd (“IQ-AI”, the “Company” and, together with its subsidiaries, the “Group”)   Publication of Annual Report   The Board of IQ-AI Ltd are pleased to present announce that the Company’s audited financial statements for the year ended 31 December 2021.  

RNS Number : 2319E IQ-AI Limited 09 March 2022   FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open   Milwaukee – 9 March 2022:  IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is

RNS Number : 0358D IQ-AI Limited 28 February 2022   28 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Total Voting Rights   In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in

RNS Number : 9343A IQ-AI Limited 08 February 2022   8 February 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Issue of shares to Mayo Clinic   Further to the Company’s announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the “New Ordinary Shares”) to Mayo

RNS Number : 3367X IQ-AI Limited 04 January 2022   4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”)   Director/PDMR Shareholding   IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary Shares”)

RNS Number : 0182W IQ-AI Limited 17 December 2021   17 December 2021 IQ-AI LIMITED (“IQ-AI” or the “Company”) IQ-AI Prepares for Phase I Clinical Trial Launch IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for encapsulating

RNS Number : 4300V IQ-AI Limited 13 December 2021   13 December 2021 IQ-AI Ltd (“IQ-AI” or the “Company”)   Director’s Interest   IQ-AI has been advised that Trevor Brown, Chief Executive of the Company, no longer has an interest in Free Association Books Limited.  Accordingly, Trevor Brown’s interest in the Company is now 32,203,457